Double trouble treatment: new combo targets skin and cholesterol together
NCT ID NCT07373847
Summary
This study is testing whether adding a cholesterol-lowering drug (recaticimab) to a standard psoriasis medication (vunakizumab) works better for people who have both conditions. It will involve 40 adults with moderate-to-severe plaque psoriasis and high cholesterol. The main goal is to see if the two-drug combination clears skin symptoms more completely by week 16 compared to the psoriasis drug alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.